Isomorphic Labs to begin human trials for AI-designed drugs

16 articles · Updated · WIRED · Apr 24

The UK-based biotech, a Google DeepMind spinoff, will test drugs designed with its AlphaFold AI, which won the 2024 Nobel Prize for chemistry.
President Max Jaderberg announced at WIRED Health in London that clinical trials are imminent, following partnerships with Eli Lilly and Novartis and a $600 million funding round.
AlphaFold technology has predicted nearly all known protein structures, revolutionizing drug discovery and enabling new medicines in oncology and immunology, with the company aiming to "solve all disease."

AlphaFold won a Nobel Prize, but can its spinoff turn predicted protein structures into profitable, life-saving drugs?

If AI only improves early-stage efficiency, is the multi-billion dollar valuation of companies like Isomorphic Labs justified?

As AI makes rare disease drugs viable, how will our healthcare systems adapt to the influx of new therapies?

With AI-designed drugs entering human trials, are regulators ready for models that learn and change unpredictably?

Can AI truly revolutionize drug discovery if it can’t invent the novel chemistry needed for breakthrough medicines?